RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000025.xml
Horm Metab Res 2008; 40(5): 299-301
DOI: 10.1055/s-2008-1076696
DOI: 10.1055/s-2008-1076696
Editorial
© Georg Thieme Verlag KG Stuttgart · New York
Update on Endocrine-related Tumors
Weitere Informationen
Publikationsverlauf
received 18.12.2007
accepted 18.12.2007
Publikationsdatum:
19. Mai 2008 (online)
![](https://www.thieme-connect.de/media/hmr/200805/lookinside/thumbnails/10.1055-s-2008-1076696-1.jpg)
Key words
endocrine-related tumors - adrenal - peptide analogues - international symposium Dresden
References
- 1 Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y, Bornstein SR. The clinically inapparent adrenal mass: update in diagnosis and management. Endocr Rev. 2004; 25 309-340
- 2 Stratakis CA, Marx SJ. Multiple endocrine neoplasias in the era of translational medicine. Horm Metab Res. 2005; 37 343-346
- 3 Stratakis CA. Adrenocortical tumors, primary pigmented adrenocortical disease (PPNAD)/Carney complex, and other bilateral hyperplasias: the NIH studies. Horm Metab Res. 2007; 39 467-473
- 4 Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U. S. adults. N Engl J Med. 2003; 348 1625-1638
- 5 Engel JB, Schally AV. Drug Insight: clinical use of agonists and antagonists of luteinizing-hormone-releasing hormone. Nat Clin Pract Endocrinol Metab. 2007; 3 157-167
- 6 Schally AV, Nagy A. Chemotherapy targeted to cancers through tumoral hormone receptors. Trends Endocrinol Metab. 2004; 15 300-310
- 7 Schally AV. New approaches to the therapy of various tumors based on peptide analogues. Horm Metab Res. 2008; 40 315-322
- 8 Engel JB, Schally AV, Dietl J, Rieger L, Honig A. Targeted therapy of breast and gynecological cancers with cytotoxic analogues of peptide hormones. Mol Pharm. 2007; 4 652-658
- 9 Buchholz S, Keller G, Schally AV. et al . Therapy of ovarian cancers with targeted cytotoxic analogs of bombesin, somatostatin, and luteinizing hormone-releasing hormone and their combinations. Proc Natl Acad Sci USA. 2006; 103 10403-10407
- 10 Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR, Pacak K. Current progress and future challenges in the biochemical diagnosis and treatment of phaeochromocytomas and paragangliomas. Horm Metab Res. 2008; 40 329-337
- 11 Pacak K, Eisenhofer G. An assessment of biochemical tests for the diagnosis of pheochromocytoma. Nat Clin Pract Endocrinol Metab. 2007; 3 744-745
- 12 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005; 366 665-675
- 13 Lenders JW, Eisenhofer G, Mannelli M, Pacak K. Phaeochromocytoma. Lancet. 2005; 366 665-675
- 14 Pacak K, Eisenhofer G, Ahlman H. et al . Pheochromocytoma: recommendations for clinical practice from the First International Symposium. October 2005. Nat Clin Pract Endocrinol Metab. 2007; 3 92-102
- 15 Benvenga S. Update on thyroid cancer. Horm Metab Res. 2008; 40 323-328
- 16 Montoya M, Brown JW, Fishman LM. Comparative effects of chemotherapeutic agents on the growth and survival of human adrenal carcinoma cells in culture. Horm Metab Res. 2008; 40 302-305
- 17 Brown JW, Prieto LM, Perez-Stable C, Montoya M, Cappell S, Fishman LM. Estrogen and progesterone lower cyclin B1 and D1 expression, block cell cycle in G2/M, and trigger apoptosis in human adrenal carcinoma cell cultures. Horm Metab Res. 2008; 40 306-310
- 18 Prieto LM, Brown JW, Perez-Stable C, Fishman LM. High dose 17β-estradiol and the α-estrogen agonist PPT trigger apoptosis in human adrenal carcinoma cells but the β-estrogen agonist DPN does not. Horm Metab Res. 2008; 40 311-314
- 19 Kasperlik-Zaluska AA, Otto M, Cichocki A. et al . Incidentally discovered adrenal tumors: a lesson from observation of 1444 patients. Horm Metab Res. 2008; 40 338-341
- 20 Grumbach MM, Biller BM, Braunstein GD. et al . Management of the clinically inapparent adrenal mass (“incidentaloma”). Ann Intern Med. 2003; 138 424-429
- 21 Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann Intern Med. 1999; 130 759-771
- 22 Johansson T, Lejonklou MH, Ekeblad S, Stålberg P, Skogseid B. Lack of nuclear expression of hairy enhancer of split-1 (HES1) in pancreatic endocrine tumors. Horm Metab Res. 2008; 40 354-359
- 23 Ziegler CG, Sicard F, Lattke P, Bornstein SR, Ehrhart-Bornstein M, Krug AW. Dehydroepiandrosterone (DHEA) induces a neuroendocrine phenotype in nerve growth factor (NGF)-stimulated chromaffin pheochromocytoma PC12 cells. Endocrinology. 2008; 149 320-328
- 24 Sicard F, Ehrhart-Bornstein M, Corbeil D. et al . Age-dependent regulation of chromaffin cell proliferation by growth factors, dehydroepiandrosterone (DHEA), and DHEA sulfate. Proc Natl Acad Sci USA. 2007; 104 2007-2012
- 25 Schwarz PE, Reimann M, Li J. et al . The metabolic syndrome - a global challenge for prevention. Horm Metab Res. 2007; 39 777-780
- 26 Boikos SA, Horvath A, Heyerdahl S. et al . Phosphodiesterase 11A expression in the adrenal cortex, primary pigmented nodular adrenocortical disease, and other corticotropin-independent lesions. Horm Metab Res. 2008; 40 347-353
Correspondence
S.R. BornsteinMD, PhD
Department of Medicine
Carl Gustav Carus
University of Dresden
Fetscherstraße 74
01307 Dresden
Germany
Telefon: +49/351/458 59 55
Fax: +49/351/458 63 98
eMail: stefan.bornstein@uniklinikum-dresden.de